[Mineralocorticoid-induced hypertension]

Area of Science:

• Endocrinology
• Genetics
• Nephrology

Background:

• Mineralocorticoid-induced hypertension pathogenesis involves complex genetic and enzymatic factors.
• Recent advances have elucidated specific molecular mechanisms underlying various forms of hypertension.
• Understanding these mechanisms is crucial for accurate diagnosis and targeted treatment.

Purpose of the Study:

• To summarize key advances in understanding the pathogenesis of mineralocorticoid-induced hypertension.
• To highlight the genetic basis of glucocorticoid remediable hypertension.
• To discuss diagnostic markers for Apparent Mineralocorticoid Excess and Liddle's syndrome.

Main Methods:

• Review of recent literature on mineralocorticoid hypertension.
• Analysis of genetic mechanisms, including hybrid gene formation and enzyme deficiencies.
• Identification of specific steroid metabolites and clinical features for diagnostic purposes.

Main Results:

• A hybrid gene, resulting from unequal crossing-over, causes glucocorticoid remediable hypertension by producing aldosterone and hybrid steroids (18-hydroxycortisol, 18-oxocortisol).
• These hybrid steroids are found in aldosterone-producing adenomas but not bilateral adrenal hyperplasia.
• Apparent Mineralocorticoid Excess is diagnosed by an increased urinary cortisol metabolite to cortisone ratio due to 11-beta-hydroxysteroid dehydrogenase type II deficiency.
• Liddle's syndrome involves constitutive activation of an amiloride-sensitive sodium channel, leading to hypokalemic hypertension.

Conclusions:

• Genetic abnormalities and enzyme deficiencies are central to mineralocorticoid-induced hypertension.
• Specific biomarkers, such as hybrid steroids and metabolite ratios, aid in differentiating hypertension subtypes.
• Further research into these pathways can lead to improved diagnostic and therapeutic strategies.